Oral-paliperidone-induced tardive dyskinesia: a case report

Wei, Han-Ting; Lai, Ya-Wen; Chen, Mu‐Hong; Chen, Ying-Sheue

doi:10.1016/j.genhosppsych.2011.11.001

Cited by 11 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Also, the occurrence of TD in association with oral paliperidone has been reported in a small number of case reports. 10,11 Several demographic and clinical factors are known to increase the risk of TD. 2 This present case has the risk factors of being female and having been exposed to 9 months of typical antipsychotic medication with relatively higher dosage.…”

Section: Discussionmentioning

confidence: 99%

Tardive Dyskinesia Induced by a Switch From Haloperidol Depot to Paliperidone Palmitate

Hsu¹,

Lin²,

Shen³

2013

JNP

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Tardive Dyskinesia Induced by a Switch From Haloperidol Depot to Paliperidone Palmitate

Hsu¹,

Lin²,

Shen³

2013

JNP

View full text Add to dashboard Cite

“…Clonazepam [41,[43][44][45][46] Studies of clonazepam the GABA-A agonist benzodiazepine (BZ) showed some effect in reducing TD [41,43]. Although no specific adverse effects would limit the usefulness of clonazepam in the elderly; the risk of drug interactions, psychomotor slowing, increased rate of falls with hip and femur …”

Section: Treatment and Managementmentioning

confidence: 99%

“…This evidence supports the hypothesis that anticholinergic therapy in patients prone to develop TD may increase the incidence of this disorder. Some studies however have shown improvement in tardive dystonia following trihexyphenidyl treatment [46,50].…”

Section: Anticholinergic Drugsmentioning

confidence: 99%

Identification and management of tardive dyskinesia: A case series and literature review

Khouzam

2015

Postgraduate Medicine

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking dopamine receptor-blocking agents. The pathophysiology of TD is complex, multifactorial and still not fully understood. Although there is no identified effective and standard treatment for TD, several agents have been tried for the management of this motor disturbance. The aim of this case series is to review the literature in regard to the identification, diagnosis and the treatment of TD with anticholinergics, anticholinergic medication withdrawal, cholinergic agents, botulinum toxin intramuscular injections, tetrabenazine, levetiracetam, propranolol and zolpidem, and to describe one case of TD that responded favorably to clonazepam and two cases of TD that responded favorably to Ginkgo biloba.

show abstract

“…Elevated Ach levels have been observed in the striatal region of the brain in animal models ( Bymaster et al, 1986 , Damsma et al, 1990 , Schulze-Delrieu, 1981 ). As a result, anticholinergic (AC) medications have been employed to correct the DA-Ach imbalance and have had some success in treating various types of drug-induced movement disorders, including akathisia and dystonia ( Greene et al, 1988 , Qiu and Lim, 2011 , Wei et al, 2012 , Waln and Jankovic, 2013 ). However, in the case of drug-induced CTD, symptoms may persist or even exacerbate after AC medication co-administration ( Brotchie et al, 2011 , Rana et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Xu¹,

Ham²,

Tivis³

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

In 2009 the U.S. Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD). In this study, we developed a multi-step biomedical informatics screening (MSBIS) approach leveraging publicly available bioactivity and drug safety data to identify concomitant drugs that mitigate the risks of MCP-induced TD. MSBIS includes (1) TargetSearch (http://dxulab.org/software) bioinformatics scoring for drug anticholinergic activity using CHEMBL bioactivity data; (2) unadjusted odds ratio (UOR) scoring for indications of TD-mitigating effects using the FDA Adverse Event Reporting System (FAERS); (3) adjusted odds ratio (AOR) re-scoring by removing the effect of cofounding factors (age, gender, reporting year); (4) logistic regression (LR) coefficient scoring for confirming the best TD-mitigating drug candidates. Drugs with increasing TD protective potential and statistical significance were obtained at each screening step. Fentanyl is identified as the most promising drug against MCP-induced TD (coefficient: −2.68; p-value < 0.01). The discovery is supported by clinical reports that patients fully recovered from MCP-induced TD after fentanyl-induced general anesthesia. Loperamide is identified as a potent mitigating drug against a broader range of drug-induced movement disorders through pharmacokinetic modifications. Using drug-induced TD as an example, we demonstrated that MSBIS is an efficient in silico tool for unknown drug-drug interaction detection, drug repurposing, and combination therapy design.

show abstract

Oral-paliperidone-induced tardive dyskinesia: a case report

Cited by 11 publications

References 14 publications

Tardive Dyskinesia Induced by a Switch From Haloperidol Depot to Paliperidone Palmitate

Tardive Dyskinesia Induced by a Switch From Haloperidol Depot to Paliperidone Palmitate

Identification and management of tardive dyskinesia: A case series and literature review

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Contact Info

Product

Resources

About